The Assessment of Cognitive Function in Lung Cancer Patients With Brain Metastases Before and After Whole-Brain Radiation Therapy

2016 ◽  
Vol 96 (2) ◽  
pp. E68-E69
Author(s):  
M. Zhou ◽  
L. Zou ◽  
Q.Q. Chen ◽  
Y. Tian ◽  
Y.X. Lian
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Cognitive Function ◽  
Brain Metastases ◽  
Cancer Patients ◽  
Whole Brain ◽  
Lung Cancer Patients ◽  
Whole Brain Radiation ◽  
Before And After ◽  
Brain Radiation

Survival and Neurologic Outcomes in a Randomized Trial of Motexafin Gadolinium and Whole-Brain Radiation Therapy in Brain Metastases

2003 ◽  
Vol 21 (13) ◽  
pp. 2529-2536 ◽  
Author(s):  
Minesh P. Mehta ◽  
Patrick Rodrigus ◽  
C.H.J. Terhaard ◽  
Aroor Rao ◽  
John Suh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Brain Metastases ◽  
Randomized Trial ◽  
Cancer Patients ◽  
Treatment Benefit ◽  
Motexafin Gadolinium ◽  
Lung Cancer Patients ◽  
Whole Brain Radiation ◽  
Brain Radiation

Purpose: This phase III randomized trial evaluated survival as well as neurologic and neurocognitive function in patients with brain metastases from solid tumors receiving whole-brain radiation therapy (WBRT) with or without motexafin gadolinium (MGd). Patients and Methods: Patients were randomly assigned to 30 Gy of WBRT ± 5 mg/kg/d MGd. Survival and time to neurologic progression determined by a blinded events review committee (ERC) were coprimary end points. Standardized investigator neurologic assessment and neurocognitive testing were evaluated. Results: Four hundred one (251 non–small-cell lung cancer) patients were enrolled. There was no significant difference by treatment arm in survival (median, 5.2 months for MGd v 4.9 months for WBRT; P = .48) or time to neurologic progression (median, 9.5 months for MGd v 8.3 months for WBRT; P = .95). Treatment with MGd improved time to neurologic progression in patients with lung cancer (median, not reached for MGd v 7.4 months for WBRT; P = .048, unadjusted). By investigator, MGd improved time to neurologic progression in all patients (median, 4.3 months for MGd v 3.8 months for WBRT; P = .018) and in lung cancer patients (median, 5.5 months for MGd v 3.7 months for WBRT; P = .025). MGd improved neurocognitive function in lung cancer patients. Conclusion: The overall results did not demonstrate significant differences by treatment arm for survival and ERC time to neurologic progression. Investigator neurologic assessments demonstrated an MGd treatment benefit in all patients. In lung cancer patients, ERC- and investigator-determined time to neurologic progression demonstrated an MGd treatment benefit. MGd may improve time to neurologic and neurocognitive progression in lung cancer.

scholarly journals The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients

2017 ◽  
Vol 12 (10) ◽  
pp. 1467-1477 ◽  
Author(s):  
Gokoulakrichenane Loganadane ◽  
Lizza Hendriks ◽  
Cécile Le Péchoux ◽  
Antonin Levy
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Small Cell ◽  
Small Cell Lung ◽  
Current Role ◽  
Lung Cancer Patients ◽  
Whole Brain Radiation ◽  
Brain Radiation
Sign in / Sign up

Export Citation Format

Share Document